- Home
- ASTH vs AUPH Comparison
ASTH vs AUPH Comparison
Compare ASTH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ASTH | AUPH |
|---|---|---|
| Founded | 1994 | 1993 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.4B | 1.6B |
| IPO Year | N/A | 1999 |
Fundamental Metrics
Financial Performance| Metric | ASTH | AUPH |
|---|---|---|
| Price | $26.95 | $14.87 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $41.33 | $17.25 |
| AVG Volume (30 Days) | 514.0K | ★ 994.8K |
| Earning Date | 02-26-2026 | 02-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.20 | ★ 0.55 |
| Revenue | ★ $2,896,452,000.00 | $265,808,000.00 |
| Revenue This Year | $58.46 | $21.76 |
| Revenue Next Year | $25.59 | $16.45 |
| P/E Ratio | $140.25 | ★ $27.03 |
| Revenue Growth | ★ 68.17 | 20.62 |
| 52 Week Low | $20.12 | $6.55 |
| 52 Week High | $39.97 | $16.54 |
Technical Indicators
Market Signals| Indicator | ASTH | AUPH |
|---|---|---|
| Relative Strength Index (RSI) | 55.21 | 40.90 |
| Support Level | $25.52 | $14.74 |
| Resistance Level | $27.80 | $15.28 |
| Average True Range (ATR) | 1.34 | 0.50 |
| MACD | 0.03 | -0.13 |
| Stochastic Oscillator | 52.06 | 7.25 |
Price Performance
Historical ComparisonAbout ASTH Astrana Health Inc.
Astrana Health Inc is a patient-centered, physician-centric integrated population health management company. The company is working to provide coordinated, outcomes-based medical care cost-effectively. It is focused on physicians providing high-quality medical care, population health management, and care coordination for patients, particularly senior patients and patients with multiple chronic conditions. The company's three reportable segments are Care Partners, Care Delivery, and Care Enablement. It generates the majority of its revenue from the Care Partners segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.